This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Lawrence Corey, MD; Dianne Silvestri, MD; King K. Holmes, MD, PhD
University of Washington School of Medicine Seattle

JAMA. 1983;249(14):1827.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

We agree with Drs Rozman and Wiedey that our study should not be construed as one that discourages further research of topical idoxuridine or other nucleoside analogues in dimethyl sulfoxide for the therapy for genital herpes. However, our investigation clearly indicates that a 30% idoxuridine-dimethyl sulfoxide mixture has no beneficial effect on the clinical course of genital herpes.

Since many authorities have claimed that the lack of clinical efficacy of many topically applied antiviral compounds has been their insolubility and poor ability to penetrate to the active site of viral replication, our desire was to pick the highest concentration of idoxuridine-dimethyl sulfoxide that would be clinically tolerated. In our hands, this was a 30% mixture. We have already stated in our article that the difference between our results and those of Parker et al could be explained if 30% idoxuridine in dimethyl sulfoxide were more toxic to normal . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?